Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2022-06-15
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well acalabrutinib works in treating patients with mantle
cell lymphoma that cannot tolerate ibrutinib. Acalabrutinib may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth.